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Introduction
The actin cytoskeleton is involved in a variety of functions from 
cell adhesion and migration, vesicle transport, and cell division 
to muscle contraction (Chhabra and Higgs, 2007; Ehler and 
Gautel, 2008; Campellone and Welch, 2010). Because sponta-
neous formation of actin filaments happens quite slowly, several 
actin nucleators have been characterized that enhance this pro-
cess. The ARP2/3 complex favors the formation of branched 
actin filaments, whereas members of the formin family promote 
F-actin assembly at the fast-growing barbed filament end to 
long unbranched filaments (Campellone and Welch, 2010). 
Formins are characterized by the presence of an FH2 (formin 
homology 2) domain. Two FH2 domains form a doughnut-
shaped dimer that can then processively move along the actin 
filaments and promote the addition of further actin monomers 
(Goode and Eck, 2007; Paul and Pollard, 2009). In addition, 
formins contain an FH1 domain that binds to profilin and prob-
ably serves to deliver G-actin, which is recruited for filament 
polymerization (Paul and Pollard, 2009). Formin family mem-
bers have been found from man to yeast and show closest   
homologies in their FH2 domains. Formin homology domain–
containing proteins (FHODs) are members of a formin subfamily 
that may also play a role in cell signaling and the regulation of tran-
scription (Young and Copeland, 2010).
Striated muscle cells are characterized by a particularly 
regular arrangement of their actin cytoskeleton in the thin fila-
ments of the sarcomeres, where the barbed end is anchored   
in the Z disc and the pointed end stretches to the middle of the 
sarcomere toward the M-band region. Thin filament length is 
strictly  controlled  by  tropomodulin,  which  caps  the  pointed 
ends (Gregorio et al., 1995). However, the concept that this ex-
tremely regular arrangement is totally static is misleading   
because metabolic labeling experiments have suggested a sur-
prisingly high turnover rate of thin filament proteins, with an 
average half-life of only 3 d (Martin, 1981). Myofibrillogenesis 
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we called this exon the “T(D/E)5XE exon” based on its charac-
teristic sequence.
Because its high degree of conservation suggested a 
preserved function, we decided to investigate the role of the   
T(D/E)5XE exon more closely. The presence of serine or threonine 
residues flanked by acidic amino acids indicated a potential CK2 
consensus sequence motif (Cox et al., 2003). Indeed, in a CK2 
in vitro phosphorylation assay, phosphorylation by CK2 was 
detected only in FHOD3-FH2 domain constructs that contained 
the alternative exon (FH2L) but not in constructs lacking it 
(FH2S) or in the FHOD1-FH2 domain. Mutation analysis re-
vealed that the second threonine (T1476) is the main target resi-
due for phosphorylation and that change of both threonines to 
alanines totally abolishes the reaction (Fig. 1 C). These phos-
phorylation results could also be confirmed in a cellular envi-
ronment and were prevented by incubation with the specific 
CK2 inhibitor DMAT (2-dimethylamino-4,5,6,7-tetrabromo-
1H-benzimidazole; Fig. 1 D).
A  previously  identified  larger  FHOD3  isoform  that  is 
caused by N-terminal alternative splicing was reported to be 
specific for the mouse heart (Kanaya et al., 2005). We therefore 
wanted to investigate whether the T(D/E)5XE exon in the FH2 
domain of FHOD3 was also spliced in a tissue-specific way. 
Different murine RNAs (tibialis anterior, soleus, atrium, ven-
tricle, uterus, lung, liver, kidney, and cortex) were tested by 
RT-PCRs with two sets of primers: the splicing-specific primer 
set E25-27, with the forward primer located in the T(D/E)5XE 
exon, and the splicing-independent primer set E24-27 (Fig. 1 E). 
Confirming the results of a previous study (Kanaya et al., 2005), 
the strongest expression of the fragment amplified by primer   
set E24-27 was found in the heart, kidney, and cortex. The de-
creased electrophoretic mobility with primer set E24-27, caused 
by the 24 additional bases, as well as the signal obtained with 
the primer set E25-27, indicated that the expression of the 
T(D/E)5XE exon is highest in soleus muscle, cardiac ventricles, 
and atria (Fig. 1 F). This suggests that the novel FHOD3 isoform 
containing the T(D/E)5XE exon is specifically expressed in stri-
ated muscle, where it is subjected to phosphorylation by CK2, 
predominantly at T1476.
The T(D/E)5XE exon targets FHOD3  
to the myofibrils
To assess the effect of the alternative splicing on biological func-
tion, we transiently transfected FHOD3, either containing or   
lacking the alternative T(D/E)5XE exon, into neonatal rat cardio-
myocytes (NRCs). Interestingly, we observed a drastically changed 
targeting pattern depending on the presence of the T(D/E)5XE 
exon. Constructs that contained the alternative T(D/E)5XE exon 
localized mainly to the myofibrils, whereas constructs lacking this 
exon formed mostly cytoplasmic aggregates (Fig. 2 A).
To investigate whether this observed change in subcellular 
localization is caused by the inclusion of the acidic T(D/E)5XE 
peptide sequence by itself or whether the phosphorylation of   
the residues T1474 and T1476 by CK2 is responsible, both threo-
nine residues were mutated to alanine or aspartate to mimic 
the unphosphorylated and phosphorylated state, respectively. 
Whereas the phosphomimicry T to D mutant of FHOD3 targeted 
has been studied extensively over the years; however, the exact 
mechanism of thin filament assembly and turnover is still un-
clear (Littlefield and Fowler, 2008; Sparrow and Schöck, 2009). 
At the earliest stages of myofibrillogenesis in the developing 
heart, actin filaments assemble in close proximity to the plasma 
membrane, and they subsequently detach and stretch through-
out the cytoplasm (Ehler et al., 2004). Currently, it is unknown 
whether actin filament nucleation during myofibrillogenesis re-
quires promoting factors and what their nature may be (Sparrow 
and Schöck, 2009). Recently, it could be shown that leiomodin, 
which is related to the pointed-end capping protein tropomodu-
lin, has strong actin filament–nucleating activity and aids myo-
fibril maintenance in cultured cardiomyocytes (Chereau et al., 
2008). However, no information is available on leiomodin’s 
function during the initial stages of myofibril assembly. Based 
on observations on the actin cytoskeleton in other cell types, the 
construction of actin filaments may depend on multiple actin 
assembly–promoting factors (Chesarone and Goode, 2009), and 
formins have been suggested as good potential candidates 
(Sparrow and Schöck, 2009).
FHOD3, a diaphanous-related formin, is expressed at high 
levels in the heart, kidney, and brain (Katoh and Katoh, 2004). 
Tissue-specific splicing in the N-terminal part results in two iso-
forms, of which only the larger is found in the heart (Kanaya   
et al., 2005). When cloning full-length FHOD3 from the heart, 
we identified an additional alternative exon, which leads to the 
insertion of eight additional amino acids at the C-terminal end 
of the FH2 domain. Based on its amino acid sequence, we called 
this additional exon the T(D/E)5XE exon. Inclusion of this exon 
is specific for striated muscle tissue and adds phosphorylation 
sites for CK2 (casein kinase 2). Phosphorylation of this site   
affects subcellular targeting and inhibits the interaction of 
FHOD3 with p62/SQSTM1 (sequestosome 1), a protein involved 
in  autophagy  (for  review  see  Rusten  and  Stenmark,  2010).   
Furthermore, we demonstrate a role for FHOD3 in actin poly-
merization and during myofibrillar maintenance in cultured   
cardiomyocytes, as well as the down-regulation of its expres-
sion in cardiomyopathy.
Results
The FHOD3 gene contains an additional 
striated muscle–specific exon that is 
expressed in a tissue-specific fashion
Because FHOD3 is the formin with the highest expression level 
in the heart, we decided to clone its full-length cDNA from an 
adult heart library to study its role in cardiomyocytes (Fig. 1 A, 
schematic representation of FHOD3). During this process, we 
identified a novel alternative exon, which inserts as exon 26 in 
humans and as exon 25 in mice (available from GenBank/
EMBL/DDBJ under accession no. HM191478; Fig. S1, exon–
intron structure of the FHOD3 gene in primates and rodents). 
This alternative exon is highly conserved between zebrafish 
and humans and encodes for eight mainly acidic amino acids 
that insert at the C-terminal end of the FH2 domain (Fig. 1,   
A [scheme] and B). To avoid confusion caused by the complexity 
of the FHOD3 gene organization between different species,   1161 Characterization of a muscle-specific FHOD3 isoform • Iskratsch et al.
observed after incubation with the CK2 inhibitor DMAT (Fig. 2 C). 
This  suggests  that  the  sarcomeric  targeting  of  FHOD3  con-
structs containing the T(D/E)5XE sequence, as well as of endog-
enous FHOD3, is regulated by CK2 phosphorylation.
FHOD3 interacts with p62/SQSTM1 in a 
phosphorylation-dependent manner
We wanted to establish whether the differential subcellular tar-
geting of FHOD3 constructs could be explained by distinct   
protein–protein interactions. Therefore, we searched for poten-
tial novel interaction partners of the FH2 domain by yeast two-
hybrid screening of a human heart cDNA library. We identified 
p62, also referred to as SQSTM1, a protein involved in ubiqui-
tin kinase signaling and proteasomal and autophagic protein 
degradation (for review see Rusten and Stenmark, 2010), as a 
to the myofibrils, constructs with the T to A mutation were 
found in cytoplasmic aggregates (Fig. 2 B). Analysis of trans-
fected NRCs by phalloidin staining to visualize F-actin revealed 
colocalization of all FHOD3 constructs with filamentous actin, 
which was also found in the aggregates (Fig. S2, A and B). The 
presence or absence of the T(D/E)5XE sequence, as well as its 
phosphorylation status (as indicated by the phosphomutant con-
structs), had also no effect on the general ability of transfected 
FHOD3 to affect actin polymerization in cells (Fig. S2 C).   
To ensure that these observations are not caused by overexpres-
sion of transiently transfected expression constructs, we looked 
at the localization of endogenous FHOD3 using an affinity- 
purified polyclonal antibody (for characterization see Fig. S3). 
Again, FHOD3 was mainly localized at the myofibrils in control 
NRCs, but a dramatic relocalization to cytoplasmic aggregates was   
Figure 1.  FHOD3 contains a novel alternative exon at the end of its FH2 domain. (A) Domain layout of the human FHOD3 splice isoform expressing the 
T(D/E)5XE exon (exon 26 in humans and exon 25 in rodents; Fig. S1). GBD, GTPase-binding domain; DID, diaphanous inhibitory domain; FH1/FH2, 
formin homology domains 1 and 2. (B) The alternative T(D/E)5XE exon of FHOD3 encodes for an evolutionarily conserved stretch of eight mainly acidic 
amino acids that introduce CK2 consensus sites. Lowercase letters are intronic, and capital letters represent exonic sequences. Splice acceptor and donor 
sites are evolutionarily conserved in all seven orthologues, with the intronic bases AG on the 5 end and GT on the 3 end. (C) GST fusion proteins of the 
FHOD3-FH2 domain containing (FH2L) or excluding (FH2S) the alternative T(D/E)5XE exon, as well as threonine to alanine mutants of the predicted target 
threonines (T1474, T1476, or both), and the FHOD1-FH2 domain were tested for CK2 in vitro phosphorylation. FH2L, but not FH2S or FHOD1-FH2, was 
phosphorylated by CK2. Mutation of T1474 or T1476 to alanine reduced phosphorylation slightly or greatly, whereas mutation of both residues completely 
abolished the phosphorylation. mM, monoclonal mouse. (D) A similar phosphorylation pattern to that seen in vitro could also be demonstrated in COS-1 
cells transfected with different GFP-tagged FHOD3 constructs and was abolished by treatment with 10 µM of the CK2 inhibitor DMAT for 24 h before lysis. 
The signal for GFP is shown as a loading control below. (E) Schematic view of the primer sets used for the RT-PCRs. (F) RT-PCR to test for tissue-specific 
expression of the alternative T(D/E)5XE exon. The amount of template mouse cDNAs was normalized against glycerine aldehyde 3-phosphate dehydro-
genase (GAPDH). The specificity of the T(D/E)5XE exon for striated muscle can either be seen with primer set E25-27 or, because of the difference in the 
electrophoretic mobility, with primer set E24-27. The top line points out the 503-bp fragment, and the bottom line indicates the 479-bp fragment, which are 
also indicated by the arrows. TA, tibialis anterior.JCB • VOLUME 191 • NUMBER 6 • 2010   1162
putative interaction partner of an FH2-LexA bait construct.   
A forced yeast two-hybrid assay revealed a stronger interaction 
with the shorter FH2 (lacking the T(D/E)5XE exon; FH2S) com-
pared with the longer FH2 (containing the T(D/E)5XE exon; FH2L) 
construct because binding to the latter was already inhibited in 
the presence of 0.5 mM 3-AT (3-amino-1,2,4-triazole), whereas 
the construct lacking the T(D/E)5XE exon was still growing in the 
presence of 5 mM 3-AT (Fig. 3 A).
GST pull-down and coimmunoprecipitation assays were 
performed to confirm the interaction of p62 with the FHOD3-
FH2 domain and full-length FHOD3 biochemically. Lysates of 
COS-1 cells that overexpressed p62 were incubated with puri-
fied FH2L- or FH2S-GST fusion proteins and FH2L-GST that 
had been incubated with CK2 before the GST pull-down assay 
(Fig. 3 B) to obtain information about a potential role of the 
CK2 phosphorylation on the binding to p62. Indeed, although 
the interaction with p62 was not affected by the insertion of the 
alternative T(D/E)5XE exon, it was disrupted by phosphoryla-
tion by CK2 (Fig. 3 B). Similarly, the mutation of the threonine 
residues to aspartic acid inhibited the binding of the full-length 
FHOD3 construct to p62 in coimmunoprecipitation experiments 
from COS-1 cell lysates (Fig. 3 C).
p62 is composed of an N-terminal Phox and Bem1p do-
main (PB1), followed by a zinc finger domain, a PEST region, 
and a C-terminal ubiquitin-associated (UBA) domain (Fig. 3 D). 
The PB1 domain is responsible for polymerization and binding 
to other PB1-containing proteins (Moscat et al., 2006), whereas 
the UBA domain binds ubiquitin noncovalently, with a prefer-
ence for polyubiquitin chains (Seibenhener et al., 2007). In an 
attempt to identify the minimal binding site required for FHOD3 
interaction, we cloned and tested different p62 deletion con-
structs (Fig. 3 D). Coimmunoprecipitation assays with lysates 
from COS-1 cells overexpressing GFP-tagged constructs of the 
p62-UBA  domain  (p62-UBA–GFP),  the  protein  without  the 
UBA domain (p62-UBA–GFP), and the PB1 domain (p62-
PB1–GFP), as well as HA-tagged FHOD3S, showed that the 
UBA-GFP construct did not bind but that interaction was de-
tected with the PB1 domain alone and with p62 lacking the 
UBA domain. This suggests that the FHOD3 binding site re-
sides in the PB1 domain of p62 (Fig. 3 E).
Upon cotransfection of FHOD3 and p62 into NRCs, a 
differential FHOD3 distribution was observed, depending on 
whether FHOD3 contained or lacked the T(D/E)5XE exon. Only 
in the latter case, a colocalization with HA-tagged p62 to cyto-
plasmic bodies occurred (Fig. 3 F, bottom). Endogenous p62 
was detected in a partially overlapping staining pattern in NRCs 
transfected with FHOD3 lacking the T(D/E)5XE exon (Fig. 3 G, 
bottom), whereas no colocalization could be detected with   
T(D/E)5XE exon–containing FHOD3 (Fig. 3 G, top). In addition, 
endogenous FHOD3 that had lost its association with the myo-
fibrils after DMAT treatment colocalized with p62 as well   
(Fig. 3 G). To confirm the identity of the p62 and FHOD3 com-
plexes as autophagosomes rather than other types of subcellular 
aggregates, we stained COS-1 cells and NRCs after double 
transfection with anti-LC3 antibodies. This revealed that the 
p62- and FHOD3-containing structures are also positive for 
LC3, which indicates their identity as autophagosomes (Fig. 4). 
Figure  2.  The  muscle-specific  FHOD3  isoform  is  targeted  to  the   
sarcomere in a phosphorylation-dependent fashion. (A and B) NRCs 
were transfected with FHOD3-HA including or lacking the alternative   
T(D/E)5XE exon (A) or after mutation of residues T1474 and T1476 to alanine 
(T>A) or aspartate (T>D; B). After 48 h, cells were fixed and stained with 
monoclonal rat anti-HA and pRb anti–myosin-binding protein C (MyBP-C). 
Constructs including the T(D/E)5XE exon targeted to the A band, whereas 
constructs lacking the T(D/E)5XE exon formed cytoplasmic aggregates. 
Mutation of the threonine residues to alanine induced the formation of 
cytoplasmic aggregates as well. No change in localization was seen   
after mutation of the threonine residues to aspartic acid. (C) Untransfected 
NRCs were treated with 10 µM of the CK2 inhibitor DMAT for 24 h and 
then fixed and stained with anti-FHOD3 and anti–-actinin antibodies. 
Untreated cells were used as a control. Similar to exogenous FHOD3, 
endogenous FHOD3 localizes to the A band but forms aggregates when 
phosphorylation by CK2 is inhibited.1163 Characterization of a muscle-specific FHOD3 isoform • Iskratsch et al.
Figure 3.  FHOD3 interacts with the p62-PB1 domain in a phosphorylation-regulated manner. (A) Yeast two-hybrid assay to test for the specificity and 
strength of the p62 interaction with the FHOD3-FH2 domain. p62-pGAD10 was transformed into yeast together with FH2L and FH2S-LexA, as well as 
with the empty LexA vector as a control, and grown on medium containing 0, 0.5, and 5.0 mM of 3-AT. p62 strongly interacts with FH2S and interacts 
much more weakly with FH2L. (B) GST pull-down assays to analyze the FHOD3–p62 interaction. Equal amounts of purified FH2L-GST, FH2S-GST, or CK2- 
phosphorylated FH2L-GST (CK2-P) were incubated with lysates of p62-GFP–transfected COS-1 cells and subjected to immunoblotting with monoclonal mouse (mM) 
anti-GFP and, subsequently, polyclonal goat anti-GST. The successful phosphorylation of FH2L-GST was controlled by incubation with monoclonal 
mouse anti–phospho-threonine (pThr). Although the presence of the unphosphorylated T(D/E)5XE exon has no effect on the interaction with p62, CK2 phos-
phorylation of FH2L-GST before the incubation strongly reduces the interaction. Inp, input. (C) Coimmunoprecipitation (IP; CoIP) of full-length FHOD3 and 
p62. Lysates of COS-1 cells, which were transfected with p62-GFP and FHOD3-HA constructs containing (FHOD3L) or excluding (FHOD3S) the T(D/E)5XE 
exon, as well as with constructs with residues T1474 and T1476 mutated to alanine (FHOD3A) or aspartic acid (FHOD3D), were immunoprecipitated with 
anti-HA and subjected to immunoblotting with anti-GFP and subsequently anti-HA antibodies. Mutation of the threonine residues to aspartic acid, but not 
to alanine, greatly reduced the interaction. (D) p62 domain structure and transfection constructs. Domains were constructed according to Simple Modular 
Architecture Research Tool (SMART) and Geetha and Wooten (2002). ZZ, zinc finger domain (ZZ type). (E) To identify the minimal binding site, COS-1 cells 
were cotransfected with FHOD3S-HA and p62-GFP constructs containing the PB1 domain, the UBA domain, or the protein without the UBA domain (UBA) 
as indicated in D. Lysates were treated as described earlier. Binding was found with the UBA and the PB1 domain, indicating that binding of FHOD3 
requires presence of the PB1 domain in p62. (F) Cotransfection of NRCs with p62-HA and FHOD3-GFP constructs. Cells were stained with monoclonal rat 
anti-HA. p62 recruits FHOD3 lacking the T(D/E)5XE exon into aggregates. (G) Transfection of NRCs with FHOD3-GFP constructs and staining with pRb 
anti-p62 show colocalization of endogenous p62 only with FHOD3 lacking the T(D/E)5XE exon. (H) Visualization of endogenous FHOD3 and p62 by   
immunofluorescence in NRCs that were treated with DMAT to inhibit CK2 demonstrates colocalization after the redistribution of FHOD3.JCB • VOLUME 191 • NUMBER 6 • 2010   1164
with the signal for sarcomeric -actinin (Fig. S3 B). Preabsorp-
tion of the FHOD3 antibodies with the antigen abolished this 
signal. Interestingly, the targeting of FHOD3 seems to be devel-
opmental stage specific and/or affected by culture conditions.   
In freshly isolated adult rat cardiomyocytes (ARCs), the signal 
was again concentrated at the Z discs with additional diffuse 
cytoplasmic signal. However, in NRCs in culture, FHOD3 
shows a wider striation pattern that partially overlaps with the   
A band (Fig. S3 B; and Fig. 2 C, top). Because the same local-
ization pattern is seen with transiently transfected full-length 
FHOD3 constructs in NRCs, we propose a differentiation 
stage–specific targeting and that FHOD3 is mainly associated 
with the Z disc of the sarcomere in fully mature and healthy 
heart tissue.
FHOD3 aids the polymerization of cardiac 
thin filaments in cyto
RNAi-mediated knockdown of FHOD3 has been shown to dis-
rupt sarcomeric structure (Taniguchi et al., 2009). We confirmed 
these observations using a slightly different experimental ap-
proach. In our case, the FHOD3-specific short hairpin RNA 
(shRNA) is transcribed from a vector rather than added directly, 
and identification of the few transfected NRCs is possible by 
GFP fluorescence, which is encoded by the same plasmid   
(Fukuzawa et al., 2008). The shRNA constructs were designed 
to target conserved regions of the rat FH2 domain. Because of 
the typically low transfection efficiency of NRCs, we performed 
the initial characterization in COS-1 cells that were cotrans-
fected with knockdown vectors and FHOD3 constructs contain-
ing the target sequences. Analysis by immunoblotting showed 
Collectively, our biochemical analysis, colocalization experi-
ments, and treatment of cells using CK2-specific inhibitors sug-
gest that FHOD3 binds to p62 in a phosphorylation-dependent 
manner. CK2 phosphorylation of the muscle-specific T(D/E)5XE 
exon in FHOD3 abolishes the interaction of the FH2 domain   
of FHOD3 with p62 and its location to autophagosomes and re-
sults in myofibrillar targeting. These two FHOD3 isoforms 
appear to have strikingly diverse functions in muscle cells, and 
their distinct roles are defined by their divergent posttranslational 
modification, which regulates the interaction with other proteins 
such as p62. In addition, the isoforms appear to show a different 
protein stability as analyzed by transfecting COS-1 cells with 
different FHOD3 constructs and treating them with cyclohexi-
mide after 24 h to inhibit de novo protein synthesis. The muscle 
isoform of FHOD3, as well as the construct that mimics phos-
phorylation, can still be detected by immunoblotting after 48 h, 
whereas constructs that can potentially interact with p62 are no 
longer seen at that time point (Fig. S4).
FHOD3 localizes to the Z disc in adult 
heart tissue
To investigate the expression and localization of endogenous 
FHOD3 in tissue, we generated an antibody against its N-terminal 
339 amino acids, which are shared between all known isoforms 
(for characterization see Fig. S3 A). Attempts to create an anti-
body that would specifically recognize the T(D/E)5XE exon 
were unsuccessful, presumably because of the low complexity 
of this sequence.
Immunostaining of longitudinal sections of mouse left 
ventricles revealed a cross-striated staining pattern that overlapped 
Figure 4.  The interaction with p62 targets FHOD3 to autophagosomes. COS-1 cells (top) and NRCs (bottom) were cotransfected with FHOD3-GFP lacking 
the T(D/E)5XE exon and p62-HA and stained with monoclonal rat anti-HA and pRb anti-LC3. p62 recruits FHOD3 into aggregates, which colabel for the 
autophagosomal marker LC3.1165 Characterization of a muscle-specific FHOD3 isoform • Iskratsch et al.
that only the specific shRNA construct, but not the construct en-
coding point-mutated shRNA, was able to reduce the expres-
sion levels of the FHOD3-GFP fusion protein (Fig. S5 A).   
An efficient knockdown was also shown by staining for endog-
enous FHOD3 in shRNA-transfected NRCs, which indicated 
70–90% knockdown after 5 d of transfection (Fig. S5 B).
To investigate FHOD3 knockdown effects on the cardio-
myocyte cytoarchitecture, NRCs were transfected with FHOD3-
shRNA or the control and incubated for 2, 5, and 8 d. NRCs 
were subsequently stained for sarcomeric markers (-actinin, 
F-actin, myosin-binding protein C, and myomesin) to examine 
potential changes to their sarcomeres and cytoskeleton. Expres-
sion of the shRNA for 2 d did not significantly change the local-
ization patterns of the sarcomeric proteins. Interestingly, the 
FHOD3 levels, as indicated by anti-FHOD3 staining, were also 
not significantly altered at that time (unpublished data). After   
5 d, however, RNA knockdown resulted in shortening of myo-
fibrils, accompanied by a reduction in the number of mature 
sarcomeres (Fig. S5, C and D). Patches of mature sarcomeres, as 
indicated by M-band localization of myomesin, were inter-
spersed with stress fiber–like structures, visualized by alpha- 
actinin staining. This phenotype may indicate impaired myofibril 
maintenance rather than defects in sarcomerogenesis and re-
flects a certain cross talk between thin and thick filaments, i.e., 
removal of one interferes with the integrity of the other over 
time in a contracting muscle cell. FHOD3 knockdown for 8 d 
further  aggravated  the  phenotype  in  transfected  myocytes   
(Fig. S5, E and F). Therefore, knockdown of FHOD3 expres-
sion levels results in a severe myofibrillar phenotype. Our knock-
down data suggest that FHOD3 plays an important role for the 
homeostasis of sarcomeric structures.
To investigate the importance of FHOD3 for the de novo 
actin polymerization in cardiomyocytes, we subjected NRCs 
with increased FHOD3 protein levels (gain of function) or in 
which endogenous FHOD3 levels were reduced by shRNA (loss 
of function) to latrunculin B treatment and recovery at different 
time points. Compared with untransfected controls, NRCs over-
expressing FHOD3 display organized sarcomeres and recovered 
thin filaments already after 30 min, as judged by -actinin and 
phalloidin staining, indicating that increased FHOD3 levels   
partially rescue latrunculin B–induced actin depolymerization   
(Fig. 5 A, bottom). Transfection of NRCs with HA-tagged mDia1, 
another member of the formin protein family, is less efficient 
because only comparatively short actin filaments surrounding 
Z bodies can be detected after 30 min of recovery (Fig. 5 B,   
bottom). Knockdown of FHOD3 protein levels in NRCs using the 
FHOD3-specific shRNA construct results in reduced thin fila-
ment and myofibrillar recovery (Fig. 5, C and D). Whereas myo-
fibrils in control cells have fully recovered 2 h after latrunculin B 
removal, only residual sarcomeric striations were visible in NRCs 
in which FHOD3 expression was knocked down. Our results 
suggest that endogenous FHOD3 is required for myofibril   
Figure 5.  FHOD3 is required for the polymerization of actin filaments in 
cardiomyocytes. (A–D) NRCs transfected with FHOD3-HA (including the 
T(D/E)5XE exon; A), mDia1-HA (B), or FHOD3-shRNA constructs (C and D) 
were treated with 20 µM latrunculin B (LT-B) overnight. Untreated trans-
fected NRCs are shown in A and B (top), whereas control shRNA-transfected 
NRCs are shown in C and D (top). Latrunculin was removed, and cells 
were left to recover for 30 min (30 min rec; A and B) or 2 h (C and D). 
Cells were stained with monoclonal rat anti-HA, monoclonal mouse anti– 
-actinin, and phalloidin (A and B) and monoclonal mouse anticardiac 
actin (anti-card. Actin) and pRb anti-FHOD3 (C) or monoclonal mouse anti– 
-actinin and phalloidin (D). (A and B) Only cells transfected with FHOD3 
have repolymerized their actin filaments after 30 min. Transfection with 
mDia1 results in a speckled phalloidin staining, indicating only reduced   
actin polymerization, whereas untransfected cells display no recovery of   
actin polymerization. (C) After 2 h, untransfected cells are starting to recover, 
with the majority of cardiac actin assembled into filaments. Colocalization 
with cardiac actin indicates an involvement of (endogenous) FHOD3 in the   
polymerization of F-actin. In contrast, no actin polymerization was detected 
after knockdown of FHOD3, further stressing the importance of this formin 
for the assembly of cardiac actin filaments (C and D).
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FHOD3 expression levels in heart tissue from muscle LIM pro-
tein (MLP) knockout mice, a model for dilated cardiomyopathy 
(Arber et al., 1997; Ehler et al., 2001). Analysis of FHOD3 iso-
forms by RT-PCR revealed a dramatic loss of isoforms contain-
ing the T(D/E)5XE exon with a concomitant up-regulation of 
T(D/E)5XE exon–lacking isoforms (Fig. 6 A). At the protein 
level, a down-regulation of total FHOD3 expression in MLP 
knockout compared with wild-type mice was seen (Fig. 6 B). 
maintenance and show for the first time that FHOD3 can aid   
actin filament polymerization in cardiomyocytes.
Down-regulation and isoform switch  
during cardiomyopathy
The observation that FHOD3 may be of importance for the as-
sembly and maintenance of cardiac myofibrils led us to investi-
gate the role of FHOD3 in cardiomyopathy. We first studied 
Figure 6.  FHOD3 expression levels are reduced in the failing heart. (A) RT-PCR analysis of samples from MLP knockout hearts and wild type (wt) using 
primers for glycerine aldehyde 3-phosphate dehydrogenase (GAPDH) for standardization and primer sets for FHOD3, amplifying all splice variants   
(E24-27), amplifying variants specific for the T(D/E)5XE exon containing (E25-27), or amplifying exclusively the T(D/E)5XE exon excluding isoform (E25). 
A dramatic change from splice isoforms containing the T(D/E)5XE exon to the isoform lacking this exon in hearts of MLP knockout mice can be detected. 
(B) The reduction of total FHOD3 (E24-27) mRNA in MLP hearts is mirrored by reduced FHOD3 protein levels in immunoblot analysis. (C and E) Immuno-
fluorescence with an anti-FHOD3 antibody shows reduced staining in sections of MLP knockout (C) and human failing hearts (E), whereas the intensity of 
the antimyomesin and anti–-actinin stainings are comparable. The reduction in muscle FHOD3 is accompanied by the appearance of autophagosome-
like structures, which also colabel for p62 (C and E, inset magnifications; C, bottom stained with monoclonal mouse anti-p62). (D) Reduced expression 
of FHOD3 is also detected by immunoblot analysis in a range of human cardiomyopathies. A quantification of the blotting is shown below. Because of 
the scarcity of the material, the blotting was only repeated once. IDCM, idiopathic dilated cardiomyopathy; VDCM, ventricular dilated cardiomyopathy; 
FDCM, familial dilated cardiomyopathy; ISHD, ischemic heart disease; PDCM, perinatal dilated cardiomyopathy.1167 Characterization of a muscle-specific FHOD3 isoform • Iskratsch et al.
with p62 and its targeting to the myofibrils. The presence of   
this isoform is a hallmark of differentiated muscle, and its   
expression is altered in a mouse model for dilated cardio-
myopathy. General knockdown of FHOD3 in NRCs interferes with 
sarcomere integrity and thin filament organization, suggesting 
that FHOD3 is crucial for myofibril maintenance. This was   
confirmed by direct actin polymerization experiments in cardio-
myocytes. Observations in failing human hearts suggest that a 
lack of FHOD3 may also be of relevance in the human setting 
of cardiomyopathy.
Discussion
Here, we describe a novel isoform of the formin family member 
FHOD3, which is specifically expressed in striated muscle. The 
isoform arises from the inclusion of an additional exon, called 
the T(D/E)5XE exon, that encodes for eight amino acids at the 
C-terminal end of the FH2 domain of FHOD3. Inclusion of this 
exon creates a phosphorylation site for CK2, which in turn regu-
lates the interaction of this FHOD3 isoform with p62/SQSTM1,   
a protein involved in muscle-specific kinase signaling, prote-
asomal degradation, and autophagy (Gautel, 2008). In addition, 
we show that FHOD3 is important for the maintenance of myo-
fibrils and aids the polymerization of actin filaments in cultured 
cardiomyocytes and that its expression is down-regulated in 
murine and human samples of failing hearts. Our results are the 
first to demonstrate the importance of a formin family member 
in heart muscle and also to correlate distinct subcellular target-
ing and binding partner interaction of a formin to a posttransla-
tional modification (Fig. 7, model).
Different  isoforms  of  FHOD3  showing  expression  re-
stricted to striated muscle were already described by Kanaya   
et al. (2005). However, these arise because of differential splic-
ing in the N-terminal half of the protein. The T(D/E)5XE exon 
Investigation of the subcellular localization of FHOD3 by   
immunofluorescence revealed Z-disc and intercalated-disc stain-
ing in wild-type tissue (Fig. 6 C). In tissue from MLP knockout 
mice, these patterns were lost, and only weaker striations could 
be observed, which tended to overlap with the M-band protein 
myomesin. Higher magnification analysis revealed, in addition, 
vesicular staining patterns for FHOD3, which partially colocal-
ized with p62. These results indicate a disease-associated iso-
form switch from the muscle FHOD3 isoform containing the 
T(D/E)5XE exon to the isoform lacking the T(D/E)5XE exon. 
This isoform switch is accompanied by changes to FHOD3 local-
ization from the myofibrils to p62-positive autophagosomes and 
may account for the reduced FHOD3 protein levels observed   
in MLP cardiomyocytes.
To see whether the down-regulation of FHOD3 in the fail-
ing heart is a peculiarity of a murine model or can be translated 
to human pathology, we investigated FHOD3 expression levels 
in different cardiomyopathy samples (Fig. 6 D). Interestingly, 
down-regulation was observed in all cases of heart disease no 
matter whether the samples originated from dilated cardio-
myopathy or from ischemic heart disease patients. In addition, we 
stained longitudinal sections of a human left ventricle of an end-
stage cardiomyopathy patient, as well as an unaffected control 
(an organ donor without indications for cardiac disease), with 
the anti-FHOD3 antibody. FHOD3 was localized to the Z discs 
and the intercalated discs also in healthy human ventricular   
cardiomyocytes (Fig. 6 E). In the diseased heart, however, a 
general down-regulation of anti-FHOD3 staining was observed, 
whereas the intensity of the -actinin staining remained compa-
rable with the control.
Collectively, our results suggest that striated muscle ex-
presses a specific splice variant of FHOD3 that introduces CK2 
phosphorylation sites at the C-terminal end of its FH2 domain. 
This posttranslational modification influences both its interaction 
Figure 7.  Model for the regulation and sub-
cellular  localization  of  different  FHOD3  iso-
forms.  The  insertion  of  the  T(D/E)5XE  exon 
into muscle FHOD3 is indicated by the yellow 
triangle at the end of the FH2 domain. Phos-
phorylation by CK2 abolishes the interaction 
of muscle FHOD3 with p62 and promotes tar-
geting to the myofibrils.JCB • VOLUME 191 • NUMBER 6 • 2010   1168
have to fuse with early endosomes for efficient degradation and 
that interference with this process inhibits autophagy and leads 
to the accumulation of p62 (Razi et al., 2009). Other members 
of the formin protein family, mDia1 and mDia2, were shown to 
be important for endosome formation, endosome transport, and 
phagocytosis in macrophages (Wallar and Alberts, 2003; Goode 
and Eck, 2007). It was also demonstrated that FNBP1L (formin-
binding protein 1–like) is necessary for autophagy of bacteria 
(Huett et al., 2009). Whether the interaction between FHOD3 
and p62 could hint at an involvement of formins such as FHOD3 
in autophagy will be interesting to investigate.
Our results indicate that FHOD3 plays a major role in the 
maintenance of myofibrils in NRCs. This confirms recent ob-
servations by Taniguchi et al. (2009), who also reported a dis-
ruption of sarcomeric structure after RNAi-mediated knockdown 
of  FHOD3.  However,  in  these  knockdown  experiments,  an   
effect is already seen after 2 d. The delayed knockdown in our 
system may potentially be because the shRNA is transcribed 
from a vector rather than added directly by transfection. The 
mechanisms of thin filament assembly and maintenance are still 
under debate (Sparrow and Schöck, 2009). Although it is known 
that the average half-life of thin filament proteins such as actin 
and troponin is 3–5 d (Martin, 1981), it is still not entirely 
clear where in the sarcomere and by which mechanism the ex-
change could happen in the contracting myocyte (Littlefield and 
Fowler, 2008). Littlefield et al. (2001) have performed elegant 
experiments that show that actin exchange at the pointed end 
(toward the M band) is 1.6 times greater than at the barbed end 
(located in the Z disc), which would be the major candidate for 
actin incorporation based on actin filament dynamics in fibro-
blasts. We could show that FHOD3, which is a predicted barbed-
end actin filament nucleator based on its analogy with other 
formins, is located mainly at the Z disc in the mature heart and 
may thus assist actin turnover or reduce barbed-end depolymer-
ization. Another actin filament nucleator that has recently been 
identified is leiomodin (Chereau et al., 2008). Leiomodin is   
related to the pointed-end capping protein tropomodulin but   
additionally contains a WH2 (Wiskott-Aldrich syndrome homol-
ogy 2) domain, which is a hallmark of actin-nucleating proteins. 
Knockdown of leiomodin similarly affects sarcomere mainte-
nance in NRCs (Chereau et al., 2008), which suggests that nu-
cleators at both the pointed end (leiomodin) and the barbed end 
(FHOD3) may be needed to assemble and maintain functional 
thin filaments.
Lastly, our observations on isoform switches and general 
down-regulation  of  FHOD3  expression  in  the  human  heart 
suggest its crucial involvement in myofibril maintenance in 
vivo and not just in cultured cardiomyocytes. There is a cer-
tain redundancy in the regulation of actin polymerization,   
as amply documented for nonmuscle cells (Chesarone and 
Goode, 2009), because thin filaments do not disappear com-
pletely. Nevertheless, other actin assembly factors cannot fully 
compensate for the down-regulation of FHOD3, or only to a 
limited extent as, for example, mDia1 in our de novo actin poly-
merization experiments in NRCs. Therefore, the loss of the adult 
heart isoform of FHOD3 might contribute to the progress   
of cardiomyopathies.
was missed in their work, presumably because a brain library 
was used for the cloning rather than a heart library as in our 
case. Although the function of different N-terminal splice vari-
ants is presently unclear, our results show the impact of the in-
clusion of the T(D/E)5XE exon on FHOD3 function, affecting 
its subcellular localization in muscle cells as well as its inter-
action with p62. The known major role of the FH2 domain is the 
nucleation of actin filaments, which requires FH2 dimerization 
because monomeric FH2 domains inhibit actin polymerization 
(Shimada et al., 2004). The FH2 domain is the most conserved 
domain within the formin family and is therefore used to clas-
sify formin family members into different categories (Higgs, 
2005). From the structural information that is available for the 
FH2 dimer of a yeast formin, it seems unlikely that the inclu-
sion of the T(D/E)5XE exon would affect dimerization because 
the main interaction occurs via the N-terminal and central part 
of the FH2 core domain (Xu et al., 2004). Our results on effi-
cient stimulation of actin polymerization by FHOD3 in cultured 
cardiomyocytes suggest that the function of the FH2 domain is 
not impaired by the insertion of the eight amino acids encoded 
by the T(D/E)5XE exon. Also, comparison of the ability of the 
different FHOD3 constructs to stimulate F-actin formation in 
HeLa cells indicates that neither the presence of the T(D/E)5XE 
exon nor the phosphorylation status (as indicated by phospho-
mutants) has an effect. Because recombinant FHOD3-FH2 
aggregated in our hands, we have been unable to study potential 
differences in actin-nucleating activity between the FH2 and 
FH2-T(D/E)5XE isoforms directly so far.
Splice variants have also been identified for other mem-
bers of the formin family, causing differences in their actin   
polymerization behavior (Wen and Rubenstein, 2009), their   
interaction with their activating small GTP-binding proteins of 
the Rho family (Lammers et al., 2008), and their susceptibility 
to inhibition by drugs (Gauvin et al., 2009). The isoform switch 
from the muscle-specific FHOD3 isoform to the isoform lack-
ing the T(D/E)5XE exon in the diseased heart parallels changes 
that have been observed for many other proteins in the heart, 
in which embryonic expression patterns are recapitulated dur-
ing cardiomyopathy (Agarkova et al., 2000; MacLellan and   
Schneider,  2000; Ahuja  et  al.,  2007).  Interestingly,  a  cardiac- 
specific knockout of the splicing factor ASF/SF2 results in severe 
cardiomyopathy, thus further stressing the importance of tissue-
specific splicing for the correct function of the heart (Cooper, 
2005; Ladd et al., 2005; Xu et al., 2005; Kalsotra et al., 2008).
The interaction of the T(D/E)5XE-lacking FHOD3 with 
p62 may be of particular importance to the role of this FHOD3 
isoform in cells. p62 is a signaling hub that also interacts with 
multiple other proteins, such as atypical PKC, TRAF6, Nbr1, 
and caspase 8, and has therefore been implicated in several cel-
lular functions that comprise NF-B signaling and cell survival, 
autophagy, apoptosis, and several myopathies (Gautel, 2008). 
Many of the p62/SQSTM1 interactions occur via its PB1 do-
main (Moscat et al., 2007), which is also the domain that ap-
pears to mediate binding to FHOD3. In addition to a potential 
effect on FHOD3 protein levels, the interaction between non-
muscle FHOD3 and p62 may also be relevant for the process of 
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4% horse serum, and 4 mM glutamine). Freshly isolated ARCs were do-
nated by F. Cuello (King’s College London, London, England, UK). For fixa-
tion, cells were incubated with 4% paraformaldehyde (Agar Scientific) in 
PBS for 10 min. To permeabilize the membrane, cells were incubated for   
5 min with 0.2% Triton X-100/PBS and then washed three times in PBS. 
Primary and secondary antibodies were diluted in antibody dilution buffer 
(1% BSA, 20 mM Tris-base, 155 mM NaCl, 2 mM EGTA, and 2 mM 
MgCl2, pH 7.5). Blocking reagent (MAXblock; Active Motif) was used be-
fore stainings with the FHOD3 antiserum according to the manufacturer’s 
instructions. The cells were incubated in the primary antibody solution for 
1 h at RT (overnight at 4°C for ARCs) and then washed three times in PBS, 
followed by incubation with the secondary antibody solution for 1 h at RT   
(5 h at RT for ARCs). For triple-immunofluorescence staining, Cy2/Alexa 
Fluor 488–, Cy3-, and Cy5/Alexa Fluor 633–conjugated secondary anti-
bodies and phalloidin (Jackson ImmunoResearch Laboratories, Inc.), as 
well as DAPI (Sigma-Aldrich), were used. Cells were mounted in 0.1 M 
Tris-HCl/glycerol (3:7) and 50 mg/ml N-propyl-gallate, pH 9.5.
Cryosections
For immunohistochemistry, tissues were cut on a cryostat (Jung CM1800; 
Leica) into 12-µm sections, mounted on poly-l-lysine–coated microscope 
slides, fixed with precooled acetone for 5 min at 20°C, and stained as 
described for the NRCs.
Human tissue
Human heart samples were obtained from the heart tissue bank set up by 
C. dos Remedios at the University of Sydney (Hospital Research Ethical 
Committee approval 09-2009-12146). Human materials were used in ac-
cordance with the ethical guidelines of King’s College London (College Re-
search Ethical Committee 04/05-74) and the current UK law.
COS-1 and HeLa cells
COS-1 or HeLa cells were cultured in maintenance medium (10% fetal 
calf serum, 1% penicillin–streptomycin, and 4 mM glutamine in DME) at 
37°C in 5% CO2. Cells were passaged at 70–80% confluency by stan-
dard trypsinization. For transfection, cells were plated onto 35-mm dishes 
and grown to 50–70% confluency. COS-1 and HeLa cells were trans-
fected with 1 µg of plasmid DNA using transfection reagent (Escort IV; 
Sigma-Aldrich) or FuGENE HD (Roche), respectively. After 48 h, cells 
were fixed for immunocytochemistry as described for the NRCs or lysed 
with 200 mM NaCl, 10 mM Tris, 0.5% NP-40, 1 mM DTT, and protease 
inhibitor (Complete, Mini; Roche), pH 7.4, for pull-down assays and co-
immunoprecipitations. For phosphorylation-sensitive experiments, 0.05 µM   
calyculin A, 0.2 mM NaVO4, and 30 mM sodium pyrophosphate were 
added to the lysis buffer.
Confocal microscopy
All confocal microscopy was performed at RT on a laser-scanning upright 
confocal microscope (LSM510; Carl Zeiss, Inc.) with solid-state (diode)   
laser excitation at 405 nm and emission at 420–480 nm, Ar laser excita-
tion at 488 nm and emission at 505–530 nm, or HeNe laser excitation at 
563 and 633 nm and emission at 560–615 nm and >650 nm using LCI 
Plan-Neofluar 25×/0.8 NA, Plan-Apochromat 63×/1.4 NA, or Plan- 
Neofluar 100×/1.3 NA oil immersion objectives.
Bacterial protein expression
Expression plasmids were transformed into the Escherichia coli expression 
strain BL21-RIL (EMD). Bacteria were incubated until the OD600 reached 
0.6, and protein expression was induced with 0.4 mM IPTG. After 3 h, 
bacterial cells were harvested by centrifugation, and cell pellets were fro-
zen in liquid nitrogen. Cells were lysed with lysozyme and DNase in 10 mM 
Tris, 200 mM NaCl, and 1 mM DTT, pH 7.4. GST fusion proteins were   
purified with glutathione Sepharose 4 fast flow beads (GE Healthcare) 
according to the manufacturer’s instructions.
GST pull-down assays and coimmunoprecipitations
The amount of GST fusion proteins bound to glutathione beads was normal-
ized by SDS-PAGE and Coomassie staining. Equal amounts of fusion pro-
teins were then added to lysates of COS-1 cells, previously transfected with 
GFP fusion constructs as described earlier. Unmodified GST peptides were 
used as a control. Samples were incubated for 90 min at 4°C on a shaking 
platform before beads were centrifuged and washed with PBS. Super-
natant was collected in new tubes. SDS samples of beads and COS-1 lysates 
were prepared and applied to SDS-PAGE and immunoblotting as described 
previously (Lange et al., 2002). For coimmunoprecipitation assays, lysates 
were incubated with anti-HA or anti-GFP antibodies for 4 h at 4°C before 
Materials and methods
RNA extraction and RT-PCRs
Mouse RNA was extracted with TRIZOL (Invitrogen) according to the man-
ufacturer’s instructions. Adult human total heart RNA was obtained from 
Agilent Technologies. cDNA pools were prepared using Moloney murine 
leukemia virus reverse transcriptase (Promega).
Murine  cDNAs  were  amplified  with  DNA  polymerase  (Phusion; 
Finnzymes) and splicing-specific (E25-27 forward, 5-ACCGATGACGAG-
GATGAAGCTGAG-3, and reverse, 5-CTCTCTGACTGGGCACTTGG-
GTGG-3; and E25 forward, 5-ATCACTGACTCTGGCAAGTTC-3, and 
reverse, 5-CTCTCTGACTGGGCACTTGGGTGG-3) or splicing-independent   
(E24-27 forward, 5-CTCATTTTTACTGTTTATGGGCCATCC-3, and re-
verse, 5-CTCTCTGACTGGGCACTTGGGTGG-3) primer sets. Amplifi-
cation  of  glycerine  aldehyde  3-phosphate  dehydrogenase  (forward, 
5-CTCAAGATTGTCAGCAATGCATCC-3, and reverse, 5-CCAGTGGAT-
GCAGGGATGATGTTC-3) was used to normalize the amount of cDNA.
Preparation of transfection constructs
The FHOD3-FH2 domain was amplified from adult human heart cDNA   
using 5-GAAGATCTGCCACCATGGTTCCTCCTCCTCCAGTG-3 forward 
and  5-CCCCGCGGCGGCTGGCTTGGGGGC-3  reverse  primers  and 
cloned into the BglII and SacII restriction sites of a pEGFP-C1 vector (Takara 
Bio Inc.). Constructs containing or excluding the alternative T(D/E)5XE exon 
were selected after sequencing. CK2 receptor residues were mutated to   
alanine  and  aspartic  acid  by  standard  site-directed  mutagenesis  using   
5-GACCAGAGGGAAGATGATCGCCGATACTGATGAGGAGGAGG-3 
(T1474A), 5-GGGAAGATGATCACCGATGCTGATGAGGAGGAGGAA-
GTTG-3 (T1476A), 5-CAGAGGGAAGATGATCGCCGATGCTGATGAG-
GAGGAGGAAG-3  (T1474A  +  T1476A),  and  5-CAGAGGGAAGAT-
GATCGATGATGATGATGAGGAGGAGGAAG-3  (T1474D  +  T1476D) 
primers. FH2-GST constructs were created by subcloning the respective 
fragments into the BglII and SacII restriction sites of a pGEX-2TK vector   
(GE Healthcare).
Full-length  FHOD3  was  amplified  from  human  heart  cDNA  with 
LA-taq polymerase (Takara Bio Inc.) using 5-ATAACCGGTGCCACCAT-
GGCCACGCTGGCTTGCC-3 forward and 5-TCCCCGCGGCAGCT-
GCAACTCCGAGG-3 reverse primers, digested with AgeI and SacII 
restriction enzymes, and cloned into the BspEI and SacII restriction sites   
of a pEGFP-C1 or HA-C1 vector. Splice isoforms were selected after se-
quencing, and phosphomutants were created as described earlier for the 
FH2 domain constructs. Diaphanous autoregulation domain (DAD) dele-
tion constructs were amplified from full-length FHOD3, and the respective 
splice isoforms and mutant constructs were amplified by using the full-
length forward and the FH2 reverse oligos and cloned as described for the 
full-length constructs.
The FHOD1-FH2 domain was amplified from adult human skeletal 
muscle cDNA using 5-GGAATTCGACAGCTCAGCCCTCCCC-3 forward 
and 5-GGGGTACCGGCGATTGTGTGTGGTG-3 reverse primers and 
cloned into the EcoRI and KpnI restriction sites of a pEGFP-C2 vector. 
mDia1 was amplified from adult human heart cDNA using 5-CCGCTC-
GAGCCACCATGGAGCCGCCCGGCGG-3  forward  and  5-GGGG-
TACCGTGCTTGCACGGCCAACC-3 reverse primers and cloned into the 
XhoI and KpnI restriction sites of a HA-C1 vector. All p62 constructs were 
a gift from M. Gautel (King’s College London, London, England, UK).
NRCs
Newborn rat hearts were digested using the neonatal cardiomyocyte iso-
lation system (Worthington Biochemical Corp.) according to the manufac-
turer and cultured basically as described previously (Lange et al., 2002). 
Cells were plated onto collagen-coated dishes (PureCol; Inamed Biomateri-
als) with a density of 0.4 × 10
6 cells per 35-mm culture dish in plating me-
dium (68% DME [Sigma-Aldrich], 16% medium M199 [Sigma-Aldrich], 
10% horse serum [Sigma-Aldrich], 5% fetal calf serum [PAA], 4 mM gluta-
mine [Sigma-Aldrich], and 1% penicillin–streptomycin [Sigma-Aldrich]).   
After 24 h in culture, the cells were transfected for 6 h with 1 µg of plasmid 
DNA per 35-mm dish with Escort III (Sigma-Aldrich) or jetPRIME (Polyplus-
transfection via Source BioScience) in antibiotics-free medium and then 
changed to maintenance medium (78% DME, 20% medium M199, 4% 
horse serum, 1% penicillin–streptomycin, 4 mM glutamine, and 0.1 mM 
phenylephrine [Sigma-Aldrich]). After 48 h, cells were fixed with 4% para-
formaldehyde (Agar Scientific) in PBS for 10 min. For long-term mainte-
nance, the cells were kept in long-term maintenance medium (20% medium 
M199, 75% DBSSK [116 mM NaCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 
5.5  mM  glucose,  32.1  mM  NaHCO3,  and  1.8  mM  CaCl2,  pH  7.2],   JCB • VOLUME 191 • NUMBER 6 • 2010   1170
Lysates were normalized by total protein content and applied to immuno-
blotting as described earlier.
Quantification of actin polymerization activity
HeLa cells were transfected as described earlier, changed to starvation 
medium (0.1% fetal calf serum, 1% penicillin–streptomycin, and 4 mM glu-
tamine in DMEM) 24 h after transfection, and fixed as described earlier   
after culturing for another 24 h. Cells were stained and imaged as de-
scribed earlier. Activation of actin polymerization was analyzed with Cell-
Profiler Image Analysis software (Carpenter et al., 2006) essentially by 
measuring the phalloidin pixel intensity and calculating the ratio between 
transfected and untransfected cells. Presented values are the means be-
tween three separate experiments with 9–12 quantified images per con-
struct per experiment.
Antibodies
For production of a polyclonal rabbit (pRb) anti-FHOD3 antibody, the   
N-terminal 339 amino acids of FHOD3 were amplified from human cDNA 
with  5-GGAATTCCGCCACCATGGCCACGCTGGCTTGCC-3  forward 
and 5-CGGGATCCCGCCCGGCACCCACTGGG-3 reverse primers and 
cloned into the EcoRI and BamHI restriction sites of a pET-3b (EMD) vector. 
The His6 fusion protein was expressed as described earlier and purified 
with 1 ml high performance columns (HisTrap; GE Healthcare) on an HPLC 
system (Äkta; GE Healthcare).
Purified His6 fusion proteins were dialyzed against PBS and concen-
trated to a final concentration of >2 µg/µl. Purity was tested by SDS-PAGE 
and Coomassie staining. The purified His6 fusion protein was sent for the 
immunization of rabbits to BioScience. Anti-FHOD3 immunsera were affin-
ity purified with antigen-coupled Sepharose columns.
The monoclonal mouse anti–sarcomeric -actinin (clone EA-53) anti-
body, as well as the pRb anti–all actin antibody, was obtained from Sigma-
Aldrich. The monoclonal mouse anti-GFP (mixture of clones 7.1 and 13.1), 
as well as the monoclonal rat anti-HA antibody (clone 3F10), was pur-
chased from Roche. The monoclonal mouse anti–phospho-threonine (clone 
4H4; donated by G. Fruhwirth, King’s College London, London, England, 
UK) and the pRb LC3B antibodies were obtained from Cell Signaling Tech-
nology, and the monoclonal mouse anti-p62 antibody was obtained from 
Abcam. The monoclonal mouse anti–cardiac actin antibody (clone Ac1-
20.4.2) was obtained from Progen. The polyclonal goat anti-GST antibody 
was obtained from GE Healthcare. The monoclonal mouse anti-myomesin 
(clone B4) was a gift from J.-C. Perriard’s Laboratory (Institute of Cell Biol-
ogy, Swiss Federal Institute of Technology Zürich Hönggerberg, Zürich, 
Switzerland). The pRb antibodies anti–myosin-binding protein C and anti-
p62 were gifts from M. Gautel. Horseradish peroxidase–conjugated anti–
mouse Igs were purchased from Dako. Horseradish peroxidase–conjugated 
anti–rabbit and anti–goat Igs were purchased from EMD. Cy2-conjugated 
anti–rabbit Igs, Cy3-conjugated anti–mouse Igs, and Cy5-conjugated anti–
rabbit and anti–mouse Igs were all purchased from Jackson Immuno-
Research Laboratories, Inc.
Image processing
Original digital images obtained either from the confocal microscope or by 
scanning of x-ray films using a scanner (Perfection 4870 Photo; Epson) 
were assembled to the figures and labeled using Photoshop or Illustrator 
(Adobe). Only linear contrast adjustments were used and were always   
applied to the entire image.
Online supplemental material
Fig. S1 shows a modified diagram of the gene structure of human (Homo 
sapiens), chimpanzee (Pan troglodytes), and mouse (M. musculus) FHOD3 
as annotated on Ensembl. Fig. S2 shows that all FHOD3 isoforms colocal-
ize with F-actin and affect actin polymerization to a comparable extent. 
Fig. S3 shows the characterization of the affinity-purified polyclonal anti-
body against FHOD3. Fig. S4 depicts that the muscle FHOD3 isoform 
shows increased stability in COS-1 cells compared with FHOD3 lacking the   
T(D/E)5XE exon and with mutants that cannot be phosphorylated. Fig. S5 
shows that knockdown of FHOD3 in NRCs leads to myofibril disassembly.   
Online  supplemental  material  is  available  at  http://www.jcb.org/cgi/ 
content/full/jcb.201005060/DC1.
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addition of BSA-blocked protein G–Sepharose (Sigma-Aldrich) for 4 h. 
Beads were separated by centrifugation, washed with PBS, boiled in SDS 
buffer, and applied to SDS-PAGE and immunoblotting. For tissue immuno-
precipitation and in cyto phosphorylation assays, the antibodies were co-
valently cross-linked to protein G–Sepharose using dimethylpimelimidate 
as a coupling agent. Samples were prepared as described earlier and ap-
plied to SDS-PAGE and immunoblotting. After incubation with the primary 
antibody, blots were incubated with immunoprecipitation detection reagent 
(Clean-Blot; Thermo Fisher Scientific) instead of the secondary antibody for 
detection of the bands with ECL.
CK2 phosphorylation assays and CK2 inhibitor experiments
For in vitro phosphorylation assays, 2.5 µg of purified GST fusion proteins 
were incubated with 50 U CK2 (New England Biolabs, Inc.) in 20 mM Tris, 
50 mM KCl, 10 mM MgCl2, and 25 µM ATP, pH 7.5, for 30 min at 30°C 
and subjected to SDS-PAGE and immunoblotting. For in cyto experiments, 
COS-1 cells or NRCs were grown for 24 h and then treated with 10 µM of 
the CK2 Inhibitor DMAT (InSolution; Merck Chemicals) for 24 h before cell 
lysis or fixation and antibody staining as described earlier.
Yeast two-hybrid assay
FHOD3-FH2 (including or excluding the alternative T(D/E)5XE exon) was 
amplified by PCR and cloned into the NcoI and BamHI sites of a modified 
pLexA vector (provided by M. Gautel). Yeast two-hybrid screening proce-
dures and -galactosidase filter assays were performed as described by 
the manufacturer. The plasmid was transferred into Saccharomyces cerevi-
siae reporter strains (NMY51; Dualsystems), which were then transformed 
with an adult human cardiac cDNA library (Takara Bio Inc.). 10
5 primary 
transformants were screened by plating on selection plates lacking the 
amino acids histidine, tryptophan, and leucine. NMY51 clones were trans-
ferred to more restricted selection plates, additionally lacking adenine for 
further exclusion of false-positive interactions. Library plasmids from posi-
tive clones were isolated, transformed into E. coli XL1-blue for amplification 
of the plasmid, and sequenced. For further verification of the interaction, 
identified clones were retransformed into the yeast together with the empty 
pLexA plasmid or the corresponding FHOD3-pLexA constructs and grown 
on selection plates lacking histidine, tryptophane, and leucine and contain-
ing 3-AT in concentrations between 0.5 and 5 mM.
shRNA
Oligonucleotides for shRNA were designed to target 22 nucleotide se-
quences in the FH1 and FH2 domains of Rattus norvegicus FHOD3 with 
ends compatible to BglII and XhoI restriction sites. Oligos (FHOD3-shRNA 
forward, 5-GATCCCCATAGACCAGTTGGAGAACAATATTCAAGAGA-
TATTGTTCTCCAACTGGTCTATTTTTTGGAAC-3, and reverse, 5-TCGAG-
TTCCAAAAAATAGACCAGTTGGAGAACAATATCTCTTGAATATTGTTCTC-
CAACTGGTCTATGGG-3;  and  control  shRNA  forward,  5-GATCCCC-
AGAAGGTTCCAAAGGTTAAAGATTCAAGAGATCTTTAACCTTTGGAA-
CCTTCTTTTTTGGAAC-3,  and  reverse,  5-TCGAGTTCCAAAAAAGA-
AGGTTCCAAAGGTTAAAGATCTCTTGAATCTTTAACCTTTGGAACCTTC-
TGGG-3) were obtained from Sigma-Aldrich. 2 nmol of forward and re-
verse oligonucleotides were diluted to 50 µl of 30 mM Hepes, 100 mM 
potassium acetate, and 2 mM magnesium acetate, pH 7.4, incubated for 
4 min at 98°C and 10 min at 70°C, and then slowly cooled down to 4°C. 
Annealed oligos were ligated into the BglII and XhoI restriction sites of a 
modified cDNA 3.1 vector, which was constructed by inserting the H1 ex-
pression cassette from pSUPER (Brummelkamp et al., 2002; donated by 
R. Agami, Netherlands Cancer Institute, Amsterdam, Netherlands), as well 
as an EGFP gene under the control of a cytomegalovirus promoter (Fukuzawa 
et al., 2008). Successful cloning was confirmed by restriction digest and 
sequencing. shRNA constructs were used to transiently transfect COS-1 
cells and NRCs as described earlier.
Actin depolymerization
NRCs were cultured and transfected as described earlier. Cells were then 
grown for 5 d in long-term maintenance medium containing 1 µg/ml vera-
pamil and then treated with 20 µM latrunculin B (VWR International) in 
long-term maintenance medium containing verapamil overnight. Latruncu-
lin was washed out, and cells were incubated for 30 min or 2 h in mainte-
nance medium containing verapamil before fixation and antibody staining 
as described earlier.
Cycloheximide
COS-1 cells were cultured and transfected as described earlier. 24 h after 
transfection, 1 µg/µl cycloheximide was added to the cells to inhibit protein 
synthesis. Cells were harvested at different time points between 0 and 72 h. 1171 Characterization of a muscle-specific FHOD3 isoform • Iskratsch et al.
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